JP2017532288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532288A5 JP2017532288A5 JP2017500891A JP2017500891A JP2017532288A5 JP 2017532288 A5 JP2017532288 A5 JP 2017532288A5 JP 2017500891 A JP2017500891 A JP 2017500891A JP 2017500891 A JP2017500891 A JP 2017500891A JP 2017532288 A5 JP2017532288 A5 JP 2017532288A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tau
- disease
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013498 tau Proteins Human genes 0.000 claims description 33
- 108010026424 tau Proteins Proteins 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 6
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 6
- 206010034010 Parkinsonism Diseases 0.000 claims description 6
- 230000005856 abnormality Effects 0.000 claims description 6
- 208000017004 dementia pugilistica Diseases 0.000 claims description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 5
- 230000000750 progressive effect Effects 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 3
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000002308 calcification Effects 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 230000007387 gliosis Effects 0.000 claims description 3
- 201000008319 inclusion body myositis Diseases 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 230000002739 subcortical effect Effects 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 2
- 210000004227 basal ganglia Anatomy 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 230000005298 paramagnetic effect Effects 0.000 claims description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462021897P | 2014-07-08 | 2014-07-08 | |
| US62/021,897 | 2014-07-08 | ||
| PCT/US2015/039205 WO2016007414A1 (en) | 2014-07-08 | 2015-07-06 | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532288A JP2017532288A (ja) | 2017-11-02 |
| JP2017532288A5 true JP2017532288A5 (show.php) | 2018-08-16 |
| JP6913018B2 JP6913018B2 (ja) | 2021-08-04 |
Family
ID=55064732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500891A Active JP6913018B2 (ja) | 2014-07-08 | 2015-07-06 | タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10132818B2 (show.php) |
| EP (1) | EP3166688B1 (show.php) |
| JP (1) | JP6913018B2 (show.php) |
| CN (1) | CN107073297B (show.php) |
| ES (1) | ES2985805T3 (show.php) |
| WO (1) | WO2016007414A1 (show.php) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| PT3334761T (pt) | 2015-08-13 | 2023-08-17 | Univ New York | Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias |
| US10988528B2 (en) | 2015-08-13 | 2021-04-27 | New York University | Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy |
| JOP20180117B1 (ar) | 2016-07-12 | 2022-03-14 | H Lundbeck As | أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها |
| WO2018049219A1 (en) * | 2016-09-08 | 2018-03-15 | Regenerative Research Foundation | Bi-functional anti-tau polypeptides and use thereof |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| BR112018067721A2 (pt) | 2017-01-04 | 2019-01-08 | H. Lundbeck A/S | anticorpos específicos para tau hiperfosforilada para o tratamento de doenças oculares |
| AU2018221049A1 (en) | 2017-02-17 | 2019-09-19 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| CN109406469B (zh) * | 2018-10-24 | 2021-04-09 | 中国医科大学 | 基于蛋白结合诱导dna双链变构的检测色氨酸的方法 |
| US12365724B2 (en) * | 2018-12-10 | 2025-07-22 | New York University | Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof |
| JP2022523333A (ja) | 2019-01-30 | 2022-04-22 | トゥルーバインディング，インコーポレイテッド | 抗ｇａｌ３抗体およびその使用 |
| CN114341364B (zh) * | 2019-07-08 | 2025-07-18 | 阿尔兹卡生物科学公司 | Tau病理靶向配体 |
| JP2022548780A (ja) * | 2019-09-23 | 2022-11-21 | マックォーリー・ユニバーシティ | タウオパチーの治療 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| WO2022046800A2 (en) * | 2020-08-24 | 2022-03-03 | University Of Southern California | Beclin 2 and uses thereof for treating cancer and neurodegenerative diseases |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ES2125854T3 (es) | 1989-08-09 | 1999-03-16 | Rhomed Inc | Radiomarcado directo de anticuerpos y otras proteinas con tecnetio o renio. |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| CA2113113A1 (en) | 1991-07-08 | 1993-01-21 | Simon W. Kantor | Thermotropic liquid crystal segmented block copolymer |
| US5434050A (en) | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| AU681071B2 (en) | 1991-12-06 | 1997-08-21 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE69424687T2 (de) | 1993-03-09 | 2000-09-07 | Genzyme Corp., Cambridge | Verfahren zur isolierung von proteinen aus milch |
| EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US6136548A (en) | 1994-11-22 | 2000-10-24 | Rutgers, The State University Of New Jersey | Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| WO1997044461A2 (en) | 1996-05-22 | 1997-11-27 | Novopharm Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| EP1150918B1 (en) | 1999-02-03 | 2004-09-15 | Biosante Pharmaceuticals, Inc. | Method of manufacturing therapeutic calcium phosphate particles |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| JP2003516718A (ja) | 1999-07-29 | 2003-05-20 | メダレックス インク | ＨＥＲ２／ｎｅｕに対するヒトモノクローナル抗体 |
| CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| ATE360392T1 (de) | 2000-11-02 | 2007-05-15 | Cornell Res Foundation Inc | In vivo multiphoton diagnostische detektion und bilddarstellung einer neurodegenerativen erkrankung |
| IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| US6821504B2 (en) | 2001-05-23 | 2004-11-23 | New York University | Detection of alzheimer's amyloid by magnetic resonance imaging |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| EP2269633A1 (en) | 2005-05-05 | 2011-01-05 | Merck Sharp & Dohme Corp. | Peptide conjugate compositions and methods for the prevention and treatment of Alzheimer's disease |
| KR20080090406A (ko) | 2005-11-28 | 2008-10-08 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
| AU2010224824B2 (en) | 2009-03-18 | 2014-02-20 | Ac Immune S.A. | Method for therapeutic use |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8748386B2 (en) * | 2009-06-10 | 2014-06-10 | New York University | Immunological targeting of pathological Tau proteins |
| RU2518291C2 (ru) | 2009-07-30 | 2014-06-10 | Пфайзер Вэксинс ЭлЭлСи | Антигенные tau-пептиды и их применения |
| WO2013050567A1 (en) * | 2011-10-07 | 2013-04-11 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
-
2015
- 2015-07-06 EP EP15818480.4A patent/EP3166688B1/en active Active
- 2015-07-06 JP JP2017500891A patent/JP6913018B2/ja active Active
- 2015-07-06 CN CN201580047108.9A patent/CN107073297B/zh active Active
- 2015-07-06 US US15/324,141 patent/US10132818B2/en active Active
- 2015-07-06 ES ES15818480T patent/ES2985805T3/es active Active
- 2015-07-06 WO PCT/US2015/039205 patent/WO2016007414A1/en not_active Ceased
-
2018
- 2018-10-04 US US16/151,555 patent/US10859582B2/en active Active
-
2020
- 2020-10-19 US US17/073,871 patent/US11519920B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532288A5 (show.php) | ||
| JP2018535921A5 (show.php) | ||
| JP2014503178A5 (show.php) | ||
| CN106574930B (zh) | 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法 | |
| JP2018534236A5 (show.php) | ||
| Hickey et al. | Diagnostic imaging of Alzheimer's disease with copper and technetium complexes | |
| US9650436B2 (en) | Antibody based reagents that specifically recognize toxic oligomeric forms of tau | |
| IL225568A (en) | Phospho-specific antibodies for tau detection | |
| JP2014502141A5 (show.php) | ||
| JP2014506244A5 (show.php) | ||
| IL310464A (en) | Anti-phf-tau antibodies and uses thereof | |
| JP2015505665A5 (show.php) | ||
| JP2018531580A5 (show.php) | ||
| JP2017504570A5 (show.php) | ||
| JP7668027B2 (ja) | 部位特異的タウリン酸化をベースとする診断および処置のための血液ベースアッセイ | |
| JP2012530055A5 (show.php) | ||
| US10191068B2 (en) | Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43 | |
| JP7558574B2 (ja) | マルチプレックスアッセイおよびその使用方法 | |
| RU2017103446A (ru) | УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ | |
| WO2020106598A1 (en) | Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies | |
| AU2020345110A1 (en) | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment | |
| US20220221795A1 (en) | Methods for detecting traumatic brain injury | |
| Bora et al. | Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry | |
| JP2015520608A5 (show.php) | ||
| WO2012149334A2 (en) | Methods and compositions for the generation and use of conformation-specific antibodies |